Advanced search
Publication Cover
Current Medical Research and Opinion Volume 21, 2005 - Issue 5
Submit an article Journal homepage
284
Views
66
CrossRef citations to date
0
Altmetric
Original Article

The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis

Dena R. Ramey Epidemiology, Merck Research Laboratories, West Point, PA, USACorrespondence[email protected]
,
Douglas J. Watson Epidemiology, Merck Research Laboratories, West Point, PA, USA
,
Chang Yu Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN, USA
,
James A. Bolognese Clinical Biostatistics, Merck Research Laboratories, Rahway, NJ, USA
,
Sean P. Curtis Immunology and Analgesia, Merck Research Laboratories, Rahway, NJ, USA
&
Alise S. Reicin Immunology and Analgesia, Merck Research Laboratories, Rahway, NJ, USA
Pages 715-722 | Accepted 18 Mar 2005, Published online: 13 Apr 2005

Citations (66)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (8)

M. Greenwald, P.M. Peloso, D. Mandel, O. Soto, A. Mehta, N. Frontera, J.A. Boice, X.J. Zhan & S.P. Curtis. (2011) Further assessment of the clinically effective dose range of etoricoxib: a randomized, double-blinded, placebo-controlled trial in rheumatoid arthritis. Current Medical Research and Opinion 27:10, pages 2033-2042.
Read now
Alaa Rostom, Katherine Muir, Catherine Dube, Angel Lanas, Emilie Jolicoeur & Peter Tugwell. (2009) Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. Drug, Healthcare and Patient Safety 1, pages 47-71.
Read now
Anthony Sebba. (2008) Efficacy and safety of etoricoxib in the treatment of osteoarthritis. Expert Review of Clinical Pharmacology 1:3, pages 345-355.
Read now
Alan Matsumoto, Agustin Melian, Arvind Shah & Sean P. Curtis. (2007) Etoricoxib versus naproxen in patients with rheumatoid arthritis: a prospective, randomized, comparator-controlled 121-week trial. Current Medical Research and Opinion 23:9, pages 2259-2268.
Read now
Jeroen P. Jansen, James Pellissier, Ernest H. Choy, Andrew Ostor, Julian T. Nash, Paul Bacon & Elke Hunsche. (2007) Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK. Current Medical Research and Opinion 23:12, pages 3069-3078.
Read now
Peter Brooks & Paul Kubler. (2006) Etoricoxib for arthritis and pain management. Therapeutics and Clinical Risk Management 2:1, pages 45-57.
Read now
C. Zerbini, Z. E. Ozturk, J. Grifka, M. Maini, S. Nilganuwong, R. Morales, M. Hupli, M. Shivaprakash & H. Giezek. (2005) Efficacy of etoricoxib 60 mg/day and diclofenac 150 mg/day in reduction of pain and disability in patients with chronic low back pain: results of a 4‐week, multinational, randomized, double-blind study. Current Medical Research and Opinion 21:12, pages 2037-2049.
Read now
Elliot V. Hersh, Edward T. Lally & Paul A. Moore. (2005) Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray?. Current Medical Research and Opinion 21:8, pages 1217-1226.
Read now

Articles from other publishers (58)

Mehran Kouchek, Sadegh Zarei, Reza Hosseiniara & MirMohammad Miri. (2023) Comparison of the Frequency of Gastrointestinal Bleeding Complications Resulting from the use of Ketorolac after Gastrointestinal Cancer Surgery with or without Gastric Ulcer Prophylaxis - A Case Control Study. The Open Anesthesiology Journal 17:1.
Crossref
Atul Mourya, Shubhra, Neha Bajwa, Ashish Baldi, Kamalinder K Singh, Manisha Pandey, Shashi Bala Singh & Jitender Madan. (2023) Potential of Phytomolecules in Alliance with Nanotechnology to Surmount the Limitations of Current Treatment Options in the Management of Osteoarthritis. Mini-Reviews in Medicinal Chemistry 23:9, pages 992-1032.
Crossref
Tanvi Goel, Deepali Bansode, Raihan Arikkattel Abdu & Sanal Dev. (2023) Molecular Docking, Microwave-Assisted Synthesis, Characterization and Pharmacological Evaluation of 2,4,5-trisubstituted Imidazole’s. Current Microwave Chemistry 10:1, pages 43-52.
Crossref
Anamika Dubey & Ashwani Kumar. 2022. Re-visiting the Rhizosphere Eco-system for Agricultural Sustainability. Re-visiting the Rhizosphere Eco-system for Agricultural Sustainability 63 87 .
I. S. Dydykina, P. S. Kovalenko & D. M. Kudinsky. (2021) Etoricoxib for generalized osteoarthritis. Case report. Modern Rheumatology Journal 15:1, pages 111-118.
Crossref
Quang A. LeJenny H. KangSun LeeDimittri Delevry. (2020) Cost-Effectiveness of Treatment Strategies with Biologics in Accordance with Treatment Guidelines for Ankylosing Spondylitis: A Patient-Level Model. Journal of Managed Care & Specialty Pharmacy 26:10, pages 1219-1231.
Crossref
A. E. Karateev. (2020) Etoricoxib can be used for chronic nonspecific back pain: a new indication of the well-known drug. Neurology, Neuropsychiatry, Psychosomatics 12:2, pages 125-130.
Crossref
A. E. Karateev. (2020) The therapeutic potential of etoricoxib in clinical practice. Modern Rheumatology Journal 14:1, pages 108-117.
Crossref
S. G. Anikin & L. I. Alekseeva. (2020) Etoricoxib in the treatment of osteoarthritis. Meditsinskiy sovet = Medical Council:2, pages 97-102.
Crossref
Tae Jun Kim, Eun Ran Kim, Sung Noh Hong, Young-Ho Kim, Yeong Chan Lee, Hye Seung Kim, Kyunga Kim & Dong Kyung Chang. (2019) Effectiveness of acid suppressants and other mucoprotective agents in reducing the risk of occult gastrointestinal bleeding in nonsteroidal anti-inflammatory drug users. Scientific Reports 9:1.
Crossref
O. S. Davydov. (2019) Facet joint osteoarthritis as a component of non-specific low back pain. Neurology, Neuropsychiatry, Psychosomatics 11:2S, pages 76-82.
Crossref
Bethan Copsey, James Buchanan, Raymond Fitzpatrick, Sarah E. Lamb, Susan J. Dutton & Jonathan A. Cook. (2019) Duration of Treatment Effect Should Be Considered in the Design and Interpretation of Clinical Trials: Results of a Discrete Choice Experiment. Medical Decision Making 39:4, pages 461-473.
Crossref
Moe H. Kyaw, Alaa Rostom, Katherine Muir, Catherine Dubé, Emilie Jolicoeur, Michel Boucher, Peter Tugwell, George Wells & Francis K.L. Chan. 2019. Evidence‐based Gastroenterology and Hepatology 4e. Evidence‐based Gastroenterology and Hepatology 4e 86 109 .
Luis Hermenegildo Martín Arias, Antonio Martín González, Rosario Sanz Fadrique & Esther Salgueiro Vázquez. (2018) Gastrointestinal safety of coxibs: systematic review and meta‐analysis of observational studies on selective inhibitors of cyclo‐oxygenase 2. Fundamental & Clinical Pharmacology 33:2, pages 134-147.
Crossref
O O Yakovleva, A O Zhamba, I O Doroshkevych & T K Vitruk. (2018) Cardiac toxicity of coxibs: mechanisms of development and their prevention. Pain medicine 3:3, pages 27-32.
Crossref
A. E. Karateev, A. M. Lila, I. S. Dydykina, P. R. Kamchatnov, S. O. Mazurenko, M. V. Naprienko, D. S. Novikova, O. P. Ostroverkhov & M. V. Pchelintsev. (2018) Personalization of the use of non-steroidal anti-inflammatory drugs for musculoskeletal diseases. Resolution on the results of the Meeting of Experts of December 13, 2017. Medical Council:18, pages 76-84.
Crossref
Allyn M Bove, Kenneth J Smith, Christopher G Bise, Julie M Fritz, John D Childs, Gerard P Brennan, J Haxby Abbott & G Kelley Fitzgerald. (2018) Exercise, Manual Therapy, and Booster Sessions in Knee Osteoarthritis: Cost-Effectiveness Analysis From a Multicenter Randomized Controlled Trial. Physical Therapy 98:1, pages 16-27.
Crossref
Wanruchada Katchamart, Pongthorn Narongroeknawin, Parawee Chevaisrakul, Pornchai Dechanuwong, Ajanee Mahakkanukrauh, Nuntana Kasitanon, Rattapol Pakchotanon, Kittiwan Sumethkul, Parichat Ueareewongsa, Sittichai Ukritchon, Thitirat Bhurihirun, Kittikorn Duangkum, Porntip Intapiboon, Samanan Intongkam, Wimol Jangsombatsiri, Kanon Jatuworapruk, Naravadee Kositpesat, Pawinee Leungroongroj, Wiyanoot Lomarat, Chonachan Petcharat, Siriluck Sittivutworapant, Patcharawan Suebmee, Pongchirat Tantayakom, Worakan Tipsing, Paijit Asavatanabodee, Praveena Chiowchanwisawakit, Chingching Foocharoen, Ajchara Koolvisoot, Worawit Louthrenoo, Boonjing Siripaitoon, Kitti Totemchokchyakarn & Tasanee Kitumnuaypong. (2017) Evidence-based recommendations for the diagnosis and management of rheumatoid arthritis for non-rheumatologists: Integrating systematic literature research and expert opinion of the Thai Rheumatism Association. International Journal of Rheumatic Diseases 20:9, pages 1142-1165.
Crossref
Annika Piirainen, Merja Kokki, Heidi Hautajärvi, Marko Lehtonen, Hannu Miettinen, Kari Pulkki, Veli-Pekka Ranta & Hannu Kokki. (2016) The Cerebrospinal Fluid Distribution of Postoperatively Administred Dexketoprofen and Etoricoxib and Their Effect on Pain and Inflammatory Markers in Patients Undergoing Hip Arthroplasty. Clinical Drug Investigation 36:7, pages 545-555.
Crossref
Gwan Gyu Song, Young Ho Seo, Jae-Hoon Kim, Sung Jae Choi, Jong Dae Ji & Young Ho Lee. (2016) Relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen in the treatment of osteoarthritisRelative Wirksamkeit und Verträglichkeit von Etoricoxib, Celecoxib und Naproxen bei der Behandlung von Osteoarthritis. Zeitschrift für Rheumatologie 75:5, pages 508-516.
Crossref
E. V. Zoryan & S. A. Rabinovich. (2016) The effectiveness and safety of nonsteroidal anti-inflammatory drugs. Rossiiskaya stomatologiya 9:3, pages 42.
Crossref
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs 738 762 .
L. E. Kristensen, A. K. Jakobsen, J. Askling, F. Nilsson & L. T. H. Jacobsson. (2015) Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population-Based Cohort Study. Arthritis Care & Research 67:8, pages 1137-1149.
Crossref
K.D. Rainsford & Ingvar Bjarnason. 2015. Ibuprofen. Ibuprofen 363 429 .
E. Carlos Rodríguez-Merchán, Hortensia De la Corte-Rodríguez & Víctor Jiménez-Yuste. 2015. Joint Surgery in the Adult Patient with Hemophilia. Joint Surgery in the Adult Patient with Hemophilia 101 104 .
E. C. Rodriguez‐Merchan, H. de la Corte‐Rodriguez & V. Jimenez‐Yuste. (2014) Efficacy of celecoxib in the treatment of joint pain caused by advanced haemophilic arthropathy in adult patients with haemophilia A . Haemophilia 20:3.
Crossref
Chaudakshetrin Pongparadee, Ester Penserga, David Jeng‐Shiang Lee, Shun‐le Chen, Ranjit Singh Gill, Abdulbar Hamid, Witsanu Kumthornthip, Yi Liu, Lucus Meliala, H Jusuf Misbach, Kian Hian Tan, Swan Sim Yeap, Sow Nam Yeo & Hsiao Yi Lin. (2012) Current considerations for the management of musculoskeletal pain in A sian countries : a special focus on cyclooxygenase‐2 inhibitors and non‐steroid anti‐inflammation drugs . International Journal of Rheumatic Diseases 15:4, pages 341-347.
Crossref
Elmar Friderichs, Thomas Christoph & Helmut Buschmann. 2003. Ullmann's Encyclopedia of Industrial Chemistry. Ullmann's Encyclopedia of Industrial Chemistry.
Elmar Friderichs, Thomas Christoph & Helmut Buschmann. 2003. Ullmann's Encyclopedia of Industrial Chemistry. Ullmann's Encyclopedia of Industrial Chemistry.
F Salvo, A Fourrier-Réglat, F Bazin, P Robinson, N Riera-Guardia, M Haag, A P Caputi, N Moore, M C Sturkenboom & A Pariente. (2011) Cardiovascular and Gastrointestinal Safety of NSAIDs: A Systematic Review of Meta-Analyses of Randomized Clinical Trials. Clinical Pharmacology & Therapeutics 89:6, pages 855-866.
Crossref
Jeroen P. Jansen & Stephanie D. Taylor. (2011) Cost-Effectiveness Evaluation of Etoricoxib versus Celecoxib and Nonselective NSAIDs in the Treatment of Ankylosing Spondylitis in Norway. International Journal of Rheumatology 2011, pages 1-14.
Crossref
Alaa Rostom, Katherine Muir, Catherine Dubé, Emilie Jolicoeur, Michel Boucher, Peter Tugwell & George Wells. 2010. Evidence‐Based Gastroenterology and Hepatology. Evidence‐Based Gastroenterology and Hepatology 139 164 .
Jeroen P. Jansen, Sabine Gaugris, Ernest H. Choy, Andrew Ostor, Julian T. Nash & Wiro Stam. (2010) Cost Effectiveness of Etoricoxib versus Celecoxib and Non-Selective NSAIDS in the Treatment of Ankylosing Spondylitis. PharmacoEconomics 28:4, pages 323-344.
Crossref
. 2010. Meyler's Side Effects of Analgesics and Anti-inflammatory Drugs. Meyler's Side Effects of Analgesics and Anti-inflammatory Drugs 223 369 .
Tjeerd-Pieter van Staa, Hubert G. Leufkens, Bill Zhang & Liam Smeeth. (2009) A Comparison of Cost Effectiveness Using Data from Randomized Trials or Actual Clinical Practice: Selective Cox-2 Inhibitors as an Example. PLoS Medicine 6:12, pages e1000194.
Crossref
Michiel W. van der Linden, Sabine Gaugris, Ernst J. Kuipers, Myrthe P. P. van Herk‐Sukel, Bart J. F. van den Bemt, Shuvayu S. Sen & Ron M. C. Herings. (2009) COX‐2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors. Pharmacoepidemiology and Drug Safety 18:10, pages 880-890.
Crossref
Katherine F. Croom & M. Asif A. Siddiqui. (2009) Etoricoxib. Drugs 69:11, pages 1513-1532.
Crossref
B. Combe, G. Swergold, J. McLay, T. McCarthy, C. Zerbini, P. Emery, L. Connors, A. Kaur, S. Curtis, L. Laine & C. P. Cannon. (2009) Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology 48:4, pages 425-432.
Crossref
Markku Kerola, Katriina Vuolteenaho, Outi Kosonen, Hannu Kankaanranta, Seppo Sarna & Eeva Moilanen. (2009) Effects of Nimesulide, Acetylsalicylic Acid, Ibuprofen and Nabumetone on Cyclooxygenase-1- and Cyclooxygenase-2-Mediated Prostanoid Production in Healthy Volunteers ex vivo . Basic & Clinical Pharmacology & Toxicology 104:1, pages 17-21.
Crossref
. 2009. MeylerâÂÂs Side Effects of Cardiovascular Drugs. MeylerâÂÂs Side Effects of Cardiovascular Drugs 557 820 .
Loren Laine, William B. White, Alaa Rostom & Marc Hochberg. (2008) COX-2 Selective Inhibitors in the Treatment of Osteoarthritis. Seminars in Arthritis and Rheumatism 38:3, pages 165-187.
Crossref
Carlos Mart?n de Argila de Prados. (2008) Aproximaci?n A. Evidencias a favor de la prescripci?n de los inhibidores selectivos de la COX-2. Gastroenterolog?a y Hepatolog?a 31, pages 34-41.
Crossref
P. I. Sidiropoulos, G. Hatemi, I.-H. Song, J. Avouac, E. Collantes, V. Hamuryudan, M. Herold, T. K. Kvien, H. Mielants, J. M. Mendoza, I. Olivieri, M. Østergaard, L. Schachna, J. Sieper, D. T. Boumpas & M. Dougados. (2008) Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists. Rheumatology 47:3, pages 355-361.
Crossref
Shaojun Shi & Ulrich Klotz. (2007) Clinical use and pharmacological properties of selective COX-2 inhibitors. European Journal of Clinical Pharmacology 64:3, pages 233-252.
Crossref
Cliff K. S. Ong & Robin A. Seymour. (2008) An evidence-based update of the use of analgesics in dentistry. Periodontology 2000 46:1, pages 143-164.
Crossref
Alejandro Escudero-Contreras, Janitzia Vazquez-Mellado Cervantes & Eduardo Collantes-Estevez. (2007) Update on the clinical pharmacology of etoricoxib, a potent cyclooxygenase-2 inhibitor. Future Rheumatology 2:6, pages 545-565.
Crossref
R Andrew Moore, Sheena Derry & Henry J McQuay. (2007) Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. BMC Musculoskeletal Disorders 8:1.
Crossref
Michael Loyd, Dale Rublee & Philip Jacobs. (2007) An economic model of long-term use of celecoxib in patients with osteoarthritis. BMC Gastroenterology 7:1.
Crossref
Katriina Vuolteenaho, Teemu Moilanen & Eeva Moilanen. (2007) Non-Steroidal Anti-Inflammatory Drugs, Cyclooxygenase-2 and the Bone Healing Process. Basic & Clinical Pharmacology & Toxicology 0:0, pages 071031053307004-???.
Crossref
Jules I. Schwartz, Nancy G. B. Agrawal, Uma A. Kher, Marina DeSmet, Paul F. CavanaughJrJr, Michel Guillaume, David L. Ebel, Shelia A. Merschman & John A. Wagner. (2007) Lack of Effect of Antacids on Single-Dose Pharmacokinetics of Etoricoxib. The Journal of Clinical Pharmacology 47:10, pages 1342-1346.
Crossref
Elmar Friderichs, Thomas Christoph & Helmut Buschmann. 2000. Ullmann's Encyclopedia of Industrial Chemistry. Ullmann's Encyclopedia of Industrial Chemistry.
Alaa Rostom, Katherine Muir, Catherine Dubé, Emilie Jolicoeur, Michel Boucher, Janet Joyce, Peter Tugwell & George W. Wells. (2007) Gastrointestinal Safety of Cyclooxygenase-2 Inhibitors: A Cochrane Collaboration Systematic Review. Clinical Gastroenterology and Hepatology 5:7, pages 818-828.e5.
Crossref
Cristina Varas‐Lorenzo, Andrew Maguire, Jordi Castellsague & Susana Perez‐Gutthann. (2006) Quantitative assessment of the gastrointestinal and cardiovascular risk‐benefit of celecoxib compared to individual NSAIDs at the population level. Pharmacoepidemiology and Drug Safety 16:4, pages 366-376.
Crossref
A. Del Favero. 2007. 116 127 .
Sumapa ChaiamnuayJeroan J. Allison & Jeffrey R. Curtis. (2006) Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs. American Journal of Health-System Pharmacy 63:19, pages 1837-1851.
Crossref
J??rgen Sch??lmerich. (2006) Nonsteroidal Anti-inflammatory Drugs Versus Selective COX-2 Inhibitors in the Upper Gastrointestinal Tract. Journal of Cardiovascular Pharmacology 47:Supplement 1, pages S67-S71.
Crossref
Christos TsoukasM. Elaine EysterSumiko ShingoSaurabh MukhopadhyayKaren M. GiallellaSean P. CurtisAlise S. ReicinAgustin Melian. (2006) Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy. Blood 107:5, pages 1785-1790.
Crossref
. (2005) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 14:12, pages i-xii.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.